MX2021014028A - Métodos y composiciones para tratar obesidad y/o trastornos de la piel. - Google Patents

Métodos y composiciones para tratar obesidad y/o trastornos de la piel.

Info

Publication number
MX2021014028A
MX2021014028A MX2021014028A MX2021014028A MX2021014028A MX 2021014028 A MX2021014028 A MX 2021014028A MX 2021014028 A MX2021014028 A MX 2021014028A MX 2021014028 A MX2021014028 A MX 2021014028A MX 2021014028 A MX2021014028 A MX 2021014028A
Authority
MX
Mexico
Prior art keywords
compositions
methods
tslp
treating obesity
skin disorders
Prior art date
Application number
MX2021014028A
Other languages
English (en)
Inventor
Taku Kambayashi
Ruth Choa
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2021014028A publication Critical patent/MX2021014028A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Se proporcionan composiciones y métodos para tratar obesidad; en ciertas modalidades, las composiciones comprenden el derivado de vitamina D3 tópico MC903; en otras modalidades, las composiciones incrementan sistémicamente los niveles de TSLP en un sujeto; en aún otras modalidades, las composiciones incluyen isoformas del péptido de TSLP y/o vectores virales adeno-asociados que contienen secuencias que expresan TSLP; los métodos que usan estas composiciones incrementan los niveles de TSLP en el sujeto y causan la pérdida selectiva de tejido adiposo blanco sin la pérdida de masa muscular.
MX2021014028A 2019-05-17 2020-05-18 Métodos y composiciones para tratar obesidad y/o trastornos de la piel. MX2021014028A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849656P 2019-05-17 2019-05-17
US202062972462P 2020-02-10 2020-02-10
PCT/US2020/033415 WO2020236722A1 (en) 2019-05-17 2020-05-18 Methods and compositions for treating obesity and/or skin disorders

Publications (1)

Publication Number Publication Date
MX2021014028A true MX2021014028A (es) 2022-02-21

Family

ID=73459398

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014028A MX2021014028A (es) 2019-05-17 2020-05-18 Métodos y composiciones para tratar obesidad y/o trastornos de la piel.

Country Status (10)

Country Link
US (1) US20220233641A1 (es)
EP (1) EP3969005A4 (es)
JP (1) JP2022533157A (es)
KR (1) KR20220034042A (es)
CN (1) CN114126623A (es)
AU (1) AU2020279960A1 (es)
BR (1) BR112021023035A2 (es)
CA (1) CA3140952A1 (es)
MX (1) MX2021014028A (es)
WO (1) WO2020236722A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19519273A1 (de) * 1995-05-22 1996-11-28 Schering Ag Topisch applizierbare Mittel zur Behandlung und Prophylaxe der Alopezie
JPH10316574A (ja) * 1997-05-16 1998-12-02 Santen Pharmaceut Co Ltd ドライアイ治療剤
WO1998053806A1 (fr) * 1997-05-26 1998-12-03 New Vision Co., Ltd. Compositions medicinales a administration topique renfermant les vitamines d et les vitamines k
US6187331B1 (en) * 1997-06-10 2001-02-13 New Vision Co., Ltd. Composition for prophylaxis and/or treatment of dry syndrome comprising vitamin D
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
CN101217868A (zh) * 2005-05-10 2008-07-09 德米普瑟尔有限公司 用于皮肤护理的组合物和方法
BRPI0920430A2 (pt) * 2008-10-22 2019-09-24 Revalesio Corp composições e métodos para tratar condições mediadas por metaloproteinase matriz 9 (mmp9)
CN102655869B (zh) * 2009-08-14 2016-08-10 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
BR112017004893A2 (pt) * 2014-09-10 2017-12-12 Univ Washington composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
WO2016103722A1 (en) * 2014-12-24 2016-06-30 Kyoto University Vitamin d3 derivatives and pharmaceutical use thereof
US10391107B2 (en) * 2015-03-16 2019-08-27 The Trustees Of The University Of Pennsylvania Compositions and methods for suppressing or reducing systemic immune response in a subject
WO2017017677A1 (en) * 2015-07-27 2017-02-02 Galmed Research And Development Ltd. Combination treatment for liver disease
CN108853503A (zh) * 2017-05-11 2018-11-23 中国科学院水生生物研究所 维生素d受体激动剂用于预防和/或治疗肥胖的用途
CN109432211B (zh) * 2019-01-03 2021-06-15 北京市中医研究所 用于银屑病和湿疹的中药组合物及其外用药物以及二者的制备方法和应用

Also Published As

Publication number Publication date
CA3140952A1 (en) 2020-11-26
AU2020279960A1 (en) 2021-12-23
JP2022533157A (ja) 2022-07-21
KR20220034042A (ko) 2022-03-17
EP3969005A1 (en) 2022-03-23
BR112021023035A2 (pt) 2022-01-25
US20220233641A1 (en) 2022-07-28
WO2020236722A1 (en) 2020-11-26
EP3969005A4 (en) 2023-10-04
CN114126623A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
EP4219724A3 (en) Compositions and methods for treating non-age-associated hearing impairment in a human subject
MX2020008763A (es) Composiciones y metodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
MY188987A (en) Aav vectors for retinal and cns gene therapy
MY190926A (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
MX2019013151A (es) Composiciones y metodos para expresar otoferlina.
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
BR112016022455A2 (pt) Uso de um sobrenadante de culturas de uma cepa de espécies de bacillus pumilus, composição cosmética ou dermofarmacêutica não natural, e, método não terapêutico para aumentar os níveis de adiponectina, aumentar a atividade mitocondrial no músculo, aumentar a resistência muscular e/ou repitelização da pele, estimular a síntese de colágeno e/ou a síntese de ácido hialurônico, tratamento de endurecimento da pele e/ou prevenção da perda de firmeza da pele
PH12020551427A1 (en) Epinephrine spray formulations
PE20200722A1 (es) Metodos de terapia genica del factor viii (fviii)
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2020013313A (es) Terapia genica cardiaca con aav para cardiomiopatia.
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
EP4257602A3 (en) Single domain antibodies for complement regulation
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2020004397A (es) Uso de suplementos de aminoacidos para mejorar la sintesis de proteinas musculares.
MX2022014085A (es) Composiciones y metodos para tratar la perdida de audicion asociada a gjb2.
MX2021014028A (es) Métodos y composiciones para tratar obesidad y/o trastornos de la piel.
MX2022010050A (es) Composiciones y metodos para tratar deficiencia auditiva no asociada con la edad en un sujeto humano.
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
TW200505426A (en) Analeptic and antidepressant combinations
TW200500063A (en) Analeptic and antidepressant combinations